enGene Therapeutics Inc. ENGN
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 88.88% | 41.33% | 34.51% | 25.51% | 41.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.58% | 17.86% | 17.18% | 126.19% | 78.69% |
| Operating Income | -13.58% | -17.86% | -17.18% | -126.19% | -78.69% |
| Income Before Tax | -13.04% | -18.19% | -20.95% | -151.16% | -102.81% |
| Income Tax Expenses | -- | -- | -- | -2,715.79% | 924.14% |
| Earnings from Continuing Operations | -12.11% | -17.09% | -20.86% | -147.60% | -104.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.11% | -17.09% | -20.86% | -147.60% | -104.91% |
| EBIT | -13.58% | -17.86% | -17.18% | -126.19% | -78.69% |
| EBITDA | -13.48% | -17.65% | -16.92% | -126.28% | -78.79% |
| EPS Basic | 17.85% | 14.33% | 8.41% | -114.12% | -77.15% |
| Normalized Basic EPS | 17.17% | 13.53% | 9.85% | -117.22% | -75.32% |
| EPS Diluted | 17.85% | 14.33% | 8.41% | -114.12% | -77.15% |
| Normalized Diluted EPS | 17.17% | 13.53% | 9.85% | -117.22% | -75.32% |
| Average Basic Shares Outstanding | 36.47% | 36.66% | 31.95% | 15.64% | 15.69% |
| Average Diluted Shares Outstanding | 36.47% | 36.66% | 31.95% | 15.64% | 15.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |